



Bruno, V. D., & Ascione, R. (2019). Commentary: Who is who in this storm? *Journal of Thoracic and Cardiovascular Surgery*, 158(2), 406-407.  
<https://doi.org/10.1016/j.jtcvs.2018.11.115>

Peer reviewed version

License (if available):  
CC BY-NC-ND

Link to published version (if available):  
[10.1016/j.jtcvs.2018.11.115](https://doi.org/10.1016/j.jtcvs.2018.11.115)

[Link to publication record in Explore Bristol Research](#)  
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Elsevier at <https://www.sciencedirect.com/science/article/pii/S0022522318332689?via%3Dihub> Please refer to any applicable terms of use of the publisher.

## University of Bristol - Explore Bristol Research

### General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:  
<http://www.bristol.ac.uk/pure/about/ebr-terms>

# The Journal of Thoracic and Cardiovascular Surgery

## Who is who in this storm?

--Manuscript Draft--

<b>Manuscript Number:</b>	JTCVS-18-2831
<b>Full Title:</b>	Who is who in this storm?
<b>Article Type:</b>	Editorial Commentary
<b>Section/Category:</b>	ACQ: Acquired
<b>Manuscript Classifications:</b>	26: Great Vessels; 26.1: Aorta
<b>Corresponding Author:</b>	Vito Domenico Bruno, M.D., PhD University of Bristol Medical School Bristol, Avon UNITED KINGDOM
<b>Corresponding Author's Institution:</b>	University of Bristol Medical School
<b>Corresponding Author's Secondary Institution:</b>	
<b>First Author:</b>	Vito Domenico Bruno, M.D., PhD
<b>Order of Authors:</b>	Vito Domenico Bruno, M.D., PhD Raimondo Ascione, MD, ChM, FETCS, FRCS
<b>Additional Information:</b>	
<b>Question</b>	<b>Response</b>
Please submit your article's <b>Central Message</b> here. The text box will limit you to 200 characters, spaces included	Translational research are becoming popular even in the field of cardiac surgery, but can a bench-based model change our clinical practice?
Please submit the <b>abbreviated legend for your Central Picture</b> . The text box will limit you to 90 characters, spaces included	V.D. Bruno (left) and R. Ascione (left)

### **Who is who in this storm?**

Vito Domenico Bruno <sup>1</sup>, Raimondo Ascione<sup>1</sup>

<sup>1</sup> Bristol Medical School - Translational Health Science, University of Bristol, Bristol, United Kingdom. Electronic address: Vito.D.Bruno@bristol.ac.uk.

### **Conflict of interest statement**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

### **Corresponding author**

Prof. Raimondo Ascione,

Bristol Medical School - Translational Health Sciences, University of Bristol

Research Floor Level 7, Bristol Royal Infirmary.

Upper Maudlin Street, BS2 8HW

Bristol (UK)

Email: R.Ascione@bristol.ac.uk

**Text Word Count: 689**

1 Cardiac surgery is an effective, evidence-based clinical practice built on decades of  
2 research spanning from basic science to rigorous large animal studies and randomized  
3 controlled trials (RCTs) in patients. This translational approach has benefited patients  
4 enormously<sup>1</sup>. More recently, we are witnessing a surge of different research methods from  
5 bench-based simulation to overnight observational studies from registries and meta-  
6 analysis that are raising questions and debates<sup>2</sup>. Concomitantly, in the era of innovation,  
7 we witness a crisis in research reproducibility<sup>3</sup>, limited reporting of registered RCTs<sup>4</sup> and  
8 a call to re-surface rigorous large animal research<sup>5</sup>. One is left wondering if these are signs  
9 of a perfect storm. At these new times, the typical cardiac surgeon looks like a passive  
10 passenger on the boat of innovation, struggling to keep the rudder straight while sailing  
11 across the troubled waters of intellectual property, commercialization, conflict of interests,  
12 harm<sup>6</sup> lack of evidence<sup>7</sup>, visibility, patient interest and evidence-based medicine. Who is  
13 who in this storm? Paulsen and colleagues<sup>8</sup> have reported a bench-based model using a 3D-  
14 printed heart simulator designed to test the long-term efficacy of two routinely used aortic  
15 conduits for valve sparing procedures. This is despite thousands of patients have already  
16 received these two conduits. The novelty of this report is that it tries to address an important  
17 clinical question on the long-term durability of the conduits using a bench-based simulator.  
18 The simulator is ingenious, modelling physiological waveforms and mechanical activities  
19 of the heart. Porcine aortic root/valves were sutured in the two conduits followed by  
20 implanting silicone tubes as mock coronary buttons. A long shot. At first look, few  
21 conflicting questions come to mind: is this simulator reliable? Can it really predict long-  
22 term durability by running for few hours? Where is the rigorous confirmatory trial in large  
23 animals? Yet, we must respect this methodological approach as modern computational

24 modelling has been shown to be effective in predicting health outcome<sup>9</sup>. Based on the  
25 evidence arising from this simulation, the authors conclude that while the Valsalva Graft  
26 accurately reflect the aortic root geometry longitudinally, its radial displacement of the  
27 valve commissures triggers abnormal forces on the leaflets affecting their long-term  
28 durability. A strong conclusion, with not a single patient operated and not a drop of blood  
29 lost! With the only variable in this simulator being the type of conduit used, it might be  
30 that the highlighted difference is genuine. Who knows? In a traditional translational  
31 research pathway, this would trigger an immediate need for in-vivo validation in a relevant  
32 large animal model. However, the simulation has several limitations. The whole system  
33 looks too artificial as opposed to a typical in-vivo model. The lack of vascular elasticity in  
34 the system is an issue. Sub-optimal surgical expertise and/or mismatch between variable  
35 sizes of porcine valve used and the fixed diameter of the conduits selected might have  
36 affected the radial displacement of the leaflets. Finally, the simulation was conducted with  
37 normal saline solution and not with blood, using a fluid with different viscosity, hence  
38 affecting dynamics. These are the practical immediate criticisms that we can raise.  
39 Translational large animal models with advanced longitudinal in-vivo imaging would  
40 provide confirmatory knowledge of the pathophysiological, mechanistic and dynamic  
41 issues associated by this study with the Valsalva Graft surgical procedure. This, in turn,  
42 would have more robust implications on the clinical scenario, possibly warranting a call  
43 for a comparative RCT? The study by Paulsen and colleagues<sup>8</sup> also highlights that  
44 undertaking isolated bench-based simulation, no matter how good it can be, does not help  
45 much in moving the field forward. This is because real translation occurs across a pipeline  
46 in which bench simulation represents only the first step. This illustrates the key learning

47 point that bench-based modelling needs to go hand-to-hand with advanced in-vivo  
48 preclinical validation in relevant models<sup>10</sup>, to facilitate translation to bedside. Translating  
49 valuable basic science into patients requires time, funding, appropriate surgical skills,  
50 translational biomedical knowledge and high experimental reproducibility. A gap in  
51 translation seems to be the main limitation of this process. Rigorous in-vivo validation in  
52 relevant preclinical models may represent an effective way to bridge the gap between  
53 bench-based science and bed side across the storm. Like a bridge over troubled waters.

54

55 References

- 56 1. Drolet BC, Lorenzi NM. Translational research: Understanding the continuum from  
57 bench to bedside. *Transl Res.* 2011;157(1):1-5. doi:10.1016/j.trsl.2010.10.002.
- 58 2. Packer M. Are Meta-Analyses a Form of Medical Fake News. *Circulation.*  
59 2017;136:2097-2099. doi:10.1161/CIRCULATIONAHA.117.030209.
- 60 3. Baker M. Is there a reproducibility crisis? *Nature.* 2016;533:452-454.  
61 doi:10.1038/533452A.
- 62 4. Who is not sharing their trial results? <https://trialstracker.ebmdatalab.net/#/>.  
63 Accessed November 27, 2018.
- 64 5. Wadman M. A trans-Atlantic transparency gap on animal experiments. *Science* (80-  
65 ). 2017;357(6347):119-120.
- 66 6. Alemzadeh H, Raman J, Leveson N et al. Adverse Events in Robotic Surgery : A  
67 Retrospective Study of 14 Years of FDA Data. *PLoS One.* 2016;104:1-20.  
68 doi:10.1371/journal.pone.0151470.
- 69 7. Medical device rules need “drastic change” to protect patients.  
70 <https://www.bbc.co.uk/news/health-46337937>. Accessed November 27, 2018.
- 71 8. Paulsen, MJ; Kasinpila P; Imbrie-Moore AM; et al. Modeling conduit choice for  
72 valve-sparing aortic root replacement on biomechanics with a 3D-printed heart  
73 simulator. *J Thorac Cardiovasc Surg.* 2018.
- 74 9. Morris PD, Narracott A, Von Tengg-Kobligk H, et al. Computational fluid dynamics  
75 modelling in cardiovascular medicine. *Heart.* 2016;102(1):18-28.

76           doi:10.1136/heartjnl-2015-308044.

77   10.   Doenst, T; Schlensak, C; Schibilsky, D et al. Do we need Basic Research in Cardiac  
78       Surgery. Thorac Cardiovasc Surg. 2018;66(1):2-6.

79



